Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea · Delayed Price · Currency is KRW 149,800
+500 (0.33%)
At close: Apr 8, 2026
Daewoong Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,570,891 | 1,422,683 | 1,375,329 | 1,280,092 | 1,152,976 |
Other Revenue | - | -0 | -0 | -0 | -0 |
| 1,570,891 | 1,422,683 | 1,375,329 | 1,280,092 | 1,152,976 | |
Revenue Growth (YoY) | 10.42% | 3.44% | 7.44% | 11.03% | 9.24% |
Cost of Revenue | 748,359 | 688,516 | 688,221 | 641,997 | 609,227 |
Gross Profit | 822,532 | 734,168 | 687,108 | 638,095 | 543,749 |
Selling, General & Admin | 427,581 | 397,216 | 376,109 | 366,091 | 315,434 |
Research & Development | 180,315 | 171,290 | 171,573 | 163,602 | 127,269 |
Amortization of Goodwill & Intangibles | 3,989 | 4,676 | 1,919 | 1,963 | 2,072 |
Other Operating Expenses | 5,116 | 4,476 | 4,382 | 4,297 | 3,554 |
Operating Expenses | 627,024 | 588,929 | 565,990 | 542,297 | 455,020 |
Operating Income | 195,508 | 145,238 | 121,118 | 95,797 | 88,729 |
Interest Expense | -12,475 | -6,986 | -13,603 | -8,406 | -10,248 |
Interest & Investment Income | 2,596 | 5,094 | 3,099 | 4,135 | 2,569 |
Earnings From Equity Investments | 46,141 | -23,153 | 29,977 | -374.54 | 257.52 |
Currency Exchange Gain (Loss) | -10,045 | 6,261 | -1,705 | -40.31 | 3,246 |
Other Non Operating Income (Expenses) | -10,811 | -25,331 | -13,423 | -43,639 | -69,962 |
EBT Excluding Unusual Items | 210,913 | 101,123 | 125,462 | 47,473 | 14,591 |
Gain (Loss) on Sale of Investments | -4,506 | -28,614 | 130.67 | -4,171 | 8,308 |
Gain (Loss) on Sale of Assets | 79.96 | -465.97 | -1,221 | 246.4 | -1,029 |
Asset Writedown | -14,654 | -15,492 | -2,372 | -5,219 | -2,109 |
Pretax Income | 191,833 | 56,550 | 121,999 | 38,330 | 19,761 |
Income Tax Expense | -1,076 | 33,204 | 1,996 | -833.51 | -10,323 |
Earnings From Continuing Operations | 192,909 | 23,347 | 120,003 | 39,163 | 30,084 |
Minority Interest in Earnings | 2,947 | 1,388 | 1,736 | 3,076 | -5,578 |
Net Income | 195,856 | 24,735 | 121,739 | 42,240 | 24,506 |
Net Income to Common | 195,856 | 24,735 | 121,739 | 42,240 | 24,506 |
Net Income Growth | 691.83% | -79.68% | 188.21% | 72.37% | 92.15% |
Shares Outstanding (Basic) | 12 | 12 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 12 | 12 | 11 | 11 | 11 |
Shares Change (YoY) | - | 0.71% | 3.21% | 0.59% | 3.21% |
EPS (Basic) | 17021.64 | 2149.65 | 10655.61 | 3815.95 | 2226.87 |
EPS (Diluted) | 17021.64 | 2149.65 | 10655.61 | 3815.95 | 2226.87 |
EPS Growth | 691.83% | -79.83% | 179.24% | 71.36% | 86.18% |
Free Cash Flow | -42,329 | -103,653 | 26,671 | 52,988 | 10,906 |
Free Cash Flow Per Share | -3678.75 | -9008.37 | 2334.47 | 4786.97 | 991.08 |
Gross Margin | 52.36% | 51.60% | 49.96% | 49.85% | 47.16% |
Operating Margin | 12.45% | 10.21% | 8.81% | 7.48% | 7.70% |
Profit Margin | 12.47% | 1.74% | 8.85% | 3.30% | 2.13% |
Free Cash Flow Margin | -2.70% | -7.29% | 1.94% | 4.14% | 0.95% |
EBITDA | 246,580 | 194,217 | 164,915 | 135,492 | 129,613 |
EBITDA Margin | 15.70% | 13.65% | 11.99% | 10.59% | 11.24% |
D&A For EBITDA | 51,072 | 48,978 | 43,797 | 39,695 | 40,883 |
EBIT | 195,508 | 145,238 | 121,118 | 95,797 | 88,729 |
EBIT Margin | 12.45% | 10.21% | 8.81% | 7.48% | 7.70% |
Effective Tax Rate | - | 58.72% | 1.64% | - | - |
Advertising Expenses | 83,366 | 73,836 | 79,245 | 80,587 | 59,081 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.